Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I guess they're gonna get f----d like the rest of us! LOL
BAG, I was wrong. I thought that these lines of credit were secured by the Bio stock! They're unsecured...
On October 30, 2006, Biofrontera, AG registered its stock on the Düsseldorf and Frankfurt, Germany stock exchanges. We anticipate that we will be able to get a line of credit facility by using the shares we own in Biofrontera, AG as collateral.
During July 2006, we borrowed $50,000 on our unsecured line of credit. [/B]The annual interest rate is Prime rate plus 2%. The line of credit expires on May 19, 2007.
On October 3, 2006, we entered into an unsecured line of credit with Clientis Ersparniskasse Erlinsbach bank. The line of credit is for 400,000 (approximately US$315,000) Swiss Francs with an annual interest rate of 4%, and the line of credit terminates on October 6, 2007. On October 3, 2006, we borrowed 400,000 Swiss Francs (approximately US$315,000) on the line of credit.
On October 26, 2006, we entered into an unsecured line of credit with Clientis Ersparniskasse Erlinsbach bank. The line of credit is for 160,000 Euros (approximately US$200,000) with an annual interest rate of 5%, and the line of credit terminates on October 26, 2007. On October 27, 2006, we borrowed 160,000 (approximately US$200,000) Euros on the line of credit.
bag, I don't have the numbers in front of me..but they're out there. I believe it was about $250,000 they borrowed against the stock...JMHO
Come on, froggy...buy in...dutchess did...obviously there is no selling pressure...you can do it...you can...DON'T YOU LIKE GREEN?
froggy, you posted: If they needed money and wished to leverage the Biofrontera asset, why didn't they just borrow against it?
They need to clean the books, for partnership. Get rid of Dutchess, reduce liabilities...etc. They will come out with a strong balance sheet...the share price will reflect that. You should buy...open that egg, buddy.
Basically "buying in" and satisfying the note. any thoughts?
Dutchess basically goes to market shorts the shares, (allowed during period of notice) drives the price down. Buys back to cover some, shorts again, drives down price. No wonder we were on the sho list for that month.. The note is satisfied...we pay. I would only expect this kind of activity if there was going to be a substantial change in the funding status. SEC wouldn't look kindly on this happening on a regular basis.
By the way: Biofrontera was quite an investment eh? quick couple a million...
To fund the acquisition of the 18% equity interest in Biofrontera in 2005, we entered into two notes with Dutchess. On June 30, 2005, we issued to Dutchess a promissory note in the amount of $1,560,000 for a purchase price of $1,300,000. This note was paid in full by the end of January 2006.
On August 1, 2005, we issued to Dutchess a second promissory note in the amount of $840,000 for a purchase price of $700,000. This note was paid in full by the end of February 2006.
DNAPRINT GENOMICS INC (DNAG)
Form: 8-K
Filing Date: 3/5/2007
An installment of €500,000 (approximately $659,000) was paid simultaneously with the execution of the agreement. The remainder of the purchase price will be paid in seven monthly installments of €500,000 (approximately $659,000) each in the months of March through September, 2007, with a final installment of €443,240 (approximately $584,000) due on October 31, 2007.
dmceng,
Notes payable at fair market value (net of discount of $670,516
for 2006 and $3,332,374 for 2005) 5,713,612
Total current liabilities 9,997,562
dm, There is no way of knowing the particulars of any possible deal. They could form a collaboration(like they do at emory) and not get a nickel. I doubt it though.
This is interesting: if anybody can comment on this I would appreciate it. TIA
I can't be certain...but was that run in December instigated by DnaPrint management? Was a put notice issued to Dutchess in Dec. 06 to pay for the note due? Were the registered securities not declared effective until FEB? Forcing Dutchess to go to market to cover 64 million shares? Very shrewd. Toss em' in the heap without issuing shares. Not sure but I think the monies borrowed against the Biofrontera stock went to paying off two other notes...June? Oct? not Dec 06 JMHO
DNAPRINT GENOMICS INC (DNAG)
Form: SB-2/A
Filing Date: 12/8/2006
This prospectus relates to the resale of up to 105,281,228 shares of our common stock by selling shareholders
On December 22, 2005, we issued to Dutchess a promissory note in the amount of $1,380,000 for a purchase price of $1,150,000. The difference of $230,000 was recorded as a discount on debt and will be amortized to interest expense over the one-year term of the note. The note is due and payable in full on December 15, 2006.
.
Roughly 40 million were for Stymkowski and Trombly, the other 64 million were to be issued to Dutchess. Max amount $600,000
this is the original investment agreement:
(B) DELIVERY OF PUT NOTICES.
(I) Subject to the terms and conditions of the Transaction Documents, and from
time to time during the Open Period, the Company may, in its sole discretion,
deliver a Put Notice to the Investor which states the Put Amount (designated in
U.S. Dollars) which the Company intends to sell to the Investor on a Closing
Date. The Put Notice shall be in the form attached hereto as Exhibit A and
incorporated herein by reference. The amount that the Company shall be entitled
to Put to the Investor (the "Put Amount") shall be equal to an amount up to a
maximum of $600,000 with respect to any single Put. During the Open Period, the
Company shall not be entitled to submit a Put Notice until after the previous
Closing has been completed. The Purchase Price for the Common Stock identified
in the Put Notice shall be equal to ninety-six percent (96%) of the average of
the two lowest closing bid price of the Common Stock during the Pricing Period.
SECTION 6. COVER.
If the number of Shares represented by any Put Notice (s) become restricted or
are no longer freely trading for any reason, and after the applicable Closing
Date, the Investor purchases, in an open market transaction or otherwise, the
Company's Common Stock (the "Covering Shares") in order to make delivery in
satisfaction of a sale of Common Stock by the Investor (the "Sold Shares"),
which delivery such Investor anticipated to make using the Shares represented by
the Put Notice (a "Buy-In"), the Company shall pay to the Investor the Buy-In
Adjustment Amount (as defined below). The "Buy-In Adjustment Amount" is the
amount equal to the excess, if any, of (A) the Investor's total purchase price
(including brokerage commissions, if any) for the Covering Shares over (B) the
net proceeds (after brokerage commissions, if any) received by the Investor from
the sale of the Sold Shares. The Company shall pay the Buy-In Adjustment Amount
to the Investor in immediately available funds immediately upon demand by the
Investor. By way of illustration and not in limitation of the foregoing, if the
Investor purchases Common Stock having a total purchase price (including
brokerage commissions) of $11,000 to cover a Buy-In with respect to the Common
Stock it sold for net proceeds of $10,000, the Buy-In Adjustment Amount which
the Company will be required to pay to the Investor will be $1,000.
http://sec.edgar-online.com/2004/10/05/0001144204-04-015688/Section7.asp
up against 20 MA resistance. A move above may just get us to .03
thanks for that stocky. "no comment" that is good.eom
Next stop .026...jmho eom
Feminist Daily News Wire
February 27, 2007
In reaction to the recent controversy, Merck has announced that it will halt its lobbying campaign to convince state legislatures to adopt mandatory vaccination policies.
http://www.feminist.org/news/newsbyte/uswirestory.asp?id=10175
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
--------------------------------------------------------------------------------
FORM 8-K
--------------------------------------------------------------------------------
CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 27, 2007
Why pay the lawyers when theranostics are the future? JMHO
JMHO...It would make sense that these monies received from the sale of the Biofrontera stock, are used to pay all notes due to Dutchess. With Dutchess out of the way (HOORAY!) and all outstanding legal issues satisfied, the new funding for ongoing operations and R&D can be put in place.
I expect a collaborative agreement to be put in place with M2gen (as we have with Emory) and big daddy Merck making sure we remain solvent. JMHO
DNAPRINT GENOMICS INC (DNAG)
Form: SB-2/A
Filing Date: 12/8/2006
At the annual shareholder meeting in June 2006, Dr. Hector J. Gomez, the Chairman of our Board of Directors, announced that we will focus on leveraging our expertise in DNA technology into the development of particular test/drug combinations, called theranostics. Theranostics is defined as the clinically-targeted integration of diagnostics and therapeutics according to Current Drug discovery September 2002. We believe theranostics adds value to the clinical trial process, improves the real-time treatment of disease, and makes treatment more cost-effective.
By leveraging our proprietary technologies, we believe we are positioned to serve the growing compliance and operational needs of pharmaceutical companies and institutional researchers. We will continue to seek product and market relationships that expand and enhance our ability to apply our technology to existing medications or new medications, improving drug efficacy and reducing patient side effects by better understanding the genetic makeup of individuals. We believe the future of drug development and drug approval as outlined by recent FDA writings will force the industry to recognize smaller market opportunities with higher efficacy profiles and significantly reduced or diminished side effects.
A critical factor to the success of research and development of pharmacogenomics assays is the ability to do high through-put genotyping. To this end, we acquired certain assets from a Canadian company and formed our subsidiary Ellipsis. Ellipsis has a Beckman-Coulter SNPstream that is capable of using a new 48-plex system, which allows for greater capacity of SNP testing at less cost. We currently have a total of three SNPstream machines enabling us to offer testing services that can validate markers at high volumes, which is especially useful in the later stages of drug and diagnostics development during large clinical trials.
To fund the acquisition of the 18% equity interest in Biofrontera in 2005, we entered into two notes with Dutchess. On June 30, 2005, we issued to Dutchess a promissory note in the amount of $1,560,000 for a purchase price of $1,300,000. This note was paid in full by the end of January 2006.
On August 1, 2005, we issued to Dutchess a second promissory note in the amount of $840,000 for a purchase price of $700,000. This note was paid in full by the end of February 2006.
DNAPRINT GENOMICS INC (DNAG)
Form: 8-K
Filing Date: 3/5/2007
An installment of €500,000 (approximately $659,000) was paid simultaneously with the execution of the agreement. The remainder of the purchase price will be paid in seven monthly installments of €500,000 (approximately $659,000) each in the months of March through September, 2007, with a final installment of €443,240 (approximately $584,000) due on October 31, 2007.
DNAPRINT GENOMICS INC (DNAG)
Form: 10QSB
Filing Date: 11/13/2006
Notes payable at fair market value (net of discount of $670,516)
$5,713,612
w2play, It's realy what it's all about. It is the worth of the company.
PII-39
DETERMINATION OF RESPONSE TO TAXOL/CARBOPLATIN
IN OVARIAN CANCER PATIENTS. T. N. Frudakis, PhD, M.
Thomas, PhD, Z. Gaskin, BS, H. J. Gomez, MD, PhD, DNAPrint
genomics Inc., Sarasota, FL.
BACKGROUND: We deal with genetic complexity through population structure to reduce the number of markers,condition case/control study results and combat the confounding influence of genetic heterogeneity and minor locus effects. This abstract describes the screening of patient genomes to construct a DNA based test for measuring Taxol/Carboplatin response proclivities.
METHODS: Pan genome maps of Ancestry Informative Markers
to estimate individual biogeographical ancestry admixture for patient samples, integrated with a case/control design were used to screen the genome.
RESULTS: Taxol/Carboplatin response was associated with Haplotypes
in 3 xenobiotic metabolism genes and a few other SNPs.
Integrating ancestry and gene-specific features enabled construction of a classification method for predicting Taxol/Carboplatin response proclivities that is capable of relatively sensitive, specific and powerful
performance in “blind” sample classification trials.
CONCLUSIONS: When gene haplotype and SNP associations
are viewed through the lens of biogeographical ancestry admixture, pattern emerges that enables relatively accurate classification of patient
response proclivities to Taxol/Carboplatin in ovarian cancer
patients.
When gene haplotype and SNP associations
are viewed through the lens of biogeographical ancestry admixture, pattern emerges that enables relatively accurate classification of patient
http://www.ascpt.org/annualmeeting2007/meetingabstracts05.pdf
Mark Bouzyk, PhD
Director, Center for Medical Genomics, Emory University
Dr Bouzyk is the new director of the Center for Medical Genomics (CMG). The CMG is a core facility that provides state of the art laboratory capabilities to enable high throughput genetic linkage and association studies ranging from candidate gene to genomic screens all supported by a robust and flexible data management infrastructure. Dr Bouzyk has come to Emory with more than eight years track record in a global pharmaceutical company, GlaxoSmithKline, where one of his roles was to serve as Director of Genetic Laboratory Sciences leading the company’s high throughput genotyping efforts in Europe.
I believe it notable that a man of his obvious credentials would provide this quote in DNAPrint's PR announcing the collaboration:
"This technology will be very useful for population stratification, and will serve as an extremely important quality control, particularly for large scale case control genetic association studies. Additionally, it will provide benefits in other areas, including pharmacogenetics,"said Dr. Mark Bouzyk, Director of Emory's Center for Medical Genomics.
PII-39
DETERMINATION OF RESPONSE TO TAXOL/CARBOPLATIN
IN OVARIAN CANCER PATIENTS. T. N. Frudakis, PhD, M.
Thomas, PhD, Z. Gaskin, BS, H. J. Gomez, MD, PhD, DNAPrint
genomics Inc., Sarasota, FL.
BACKGROUND: We deal with genetic complexity through population
structure to reduce the number of markers, condition case/
control study results and combat the confounding influence of genetic
heterogeneity and minor locus effects. This abstract describes the
screening of patient genomes to construct a DNA based test for
measuring Taxol/Carboplatin response proclivities.
METHODS: Pan genome maps of Ancestry Informative Markers
to estimate individual biogeographical ancestry admixture for patient
samples, integrated with a case/control design were used to screen the
genome.
RESULTS: Taxol/Carboplatin response was associated with Haplotypes
in 3 xenobiotic metabolism genes and a few other SNPs.
Integrating ancestry and gene-specific features enabled construction
of a classification method for predicting Taxol/Carboplatin response
proclivities that is capable of relatively sensitive, specific and powerful
performance in “blind” sample classification trials.
CONCLUSIONS: When gene haplotype and SNP associations
are viewed through the lens of biogeographical ancestry admixture,
pattern emerges that enables relatively accurate classification of patient
response proclivities to Taxol/Carboplatin in ovarian cancer
patients.
http://www.ascpt.org/annualmeeting2007/meetingabstracts05.pdf
I want to apologize for an earlier post or two...anyone offended. I was out of line.
DNAPRINT GENOMICS INC (DNAG)
Form: 10QSB
Filing Date: 11/13/2006
On September 14, 2006, we filed a registration statement to register 260,281,228 shares of our common stock of which 175,000,000 shares were for the shares underlying the convertible debentures held by Dutchess and 45,000,000 shares were for the shares underlying the convertible debentures held by La Jolla
Notes payable at fair market value (net of discount of $670,516) 5,713,612
Convertible notes Warrants and options 323,149,861 shares
That 5 million is what they owe on notes.
I can't find it right now but I remember seeing in one of the filings that if the notes were paid with funding acquired during the term of the put notice and the notes were paid with that funding, a penalty would be incurred.
I don't believe that the sale of the Biofrontera stock would be considered "outside financing".
It would make sense if there were other sources of funding, that they would sell the Bio stock to pay the notes without incurring a penalty.
If we get a filing tomorrow stating that shares are being issued to pay the March note...I would say that we need the money for ongoing operations. Not a good sign.
I believe we'll know tomorrow if the roast is for real..
JMHO is that common sense or nonsensical?
JMHO I'm not sure if that is common sense or nonsesical.
http://yahoo.brand.edgar-online.com/fetchFilingFrameset.aspx?FilingID=4757816&Type=HTML
trog, how soon you forget...is PONV ready? Emend with a test. Enviously green, eh?....
EMEND? (aprepitant) Helps Prevent Nausea/Vomiting for Breast Cancer Patients
the regimen including EMEND (day 1: EMEND 125 mg one hour before chemotherapy, ondansetron 8 mg 30-60 minutes before chemotherapy
EMEND? is a registered trademark of Merck & Co
http://www.medicalnewstoday.com/medicalnews.php?newsid=23074
Ondansetron
Through collaboration with the Moffitt Cancer Research Center in Tampa, FL, we are investigating the genetic basis of Ondansetron response. Ondansetron is an anti-emetic for the alleviation of post-operative nausea and vomiting (PONV), but normal doses of the drug do not elicit the desired effect in some patients. A genetic test for predicting Ondansetron response could help reduce extreme discomfort many patients feel after surgery.
March 29, 2004 DNAPrint™ genomics, Inc. Forms Joint Research Program with the H. Lee Moffitt Cancer Center and Research Institute
mlb4nd, this filing is just what the doctor ordered...IF..they are not going to issue more shares on top to pay Dutchess tomorrow (note payable). They are taking cash instead of borrowing against the asset. That sounds like they are cleaning the books. Why? No more shares sounds good...that should push up the price. JMHO
pennies, things are happening very fast.
The gene expression tests were 90 percent accurate for both receptors, which makes them comparable to, if not better than, existing pathology tests.
http://www.sciencedaily.com/releases/2007/02/070214221109.htm
I want to be...You sure do...dont'cha'? Have you ever posted anything of worth?
I suspect that this is below the "COMMON SENSE" that is posted on this board daily:
Results with New Integrase Inhibitor Plus FUZEON and Boosted Protease Inhibitor Show Remarkable Undetectable Rate of 98 Percent in Treatment-Experienced HIV Patients
http://72.14.209.104/search?q=cache:Vq_zeQ-Q_Z4J:www.smartbrief.com/news/fdli/industryBW-detail.jsp%...
Merck has a compound that eradicates HIV. The trials were accelerated at Emory running concurrently with our collaboration agreement with Emory.
HOW OUTLANDISH OF ME!!
HOW NON-SENSICAL!!!
Let's put DNAG aside. Merck has a compound that eradicates HIV. Can anybody here comment on that? Can any SHAREHOLDER[/B] of DNAG tell me what Emory and DnaPrint are collaborating on?
Morons...
People with common sense DON'T invest in pennystocks...BUT HEY,
TO DAAAA MOOOOOON!
Iw2b, maybe this is the kind of post that makes more sense around here:
TO DAAAAAA MOOOOOOOONNNNN!
GOOD LUCK TO ALL, SIGNING OFF...
JOHNNYFIBER
stockholder101, can you please verify this...from your post:
M2GEN remains the confirmed partner. TIA
We are beginning to reap the benefits of computational biology technology acquired by the Company in November 2005," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "This first generation of EPOFusion is designed to support the basic science studies required for drugs before human testing. Our Computational Biology Division will be advancing EPOFusion to a second generation model, using knowledge gained in the preclinical phase, for an expanded version (EPOFusion II) used to simulate clinical (human) studies."
http://www.hpcwire.com/hpc/660244.html
It's got a new name:
March 1, 2007 (Los Angeles) — Merck unveiled a new name for its integrase inhibitor, raltegravir, along with 16-week data on a pair of phase 3 clinical trials at the 14th Conference on Retroviruses and Opportunistic Infections.
The first-in-class compound is a small molecule that blocks an early stage in the HIV lifecycle, the integration of the virus into host cell DNA. The drug formally was known as MK-0518.
The Benchmrk 1 and 2 studies respectively enrolled 350 and 349 patients with triple-class drug failure defined as genotypic/phenotypic
In the patients who added enfurvitide or darunavir for the first time as part of OBT, viral load dropped below 400 copies/mL in 90%, while 98% of those who received both drugs for the first time achieved a viral load less than 400 copies/mL, he said.
http://www.medscape.com/viewarticle/552990
Frankly, I think there will be a cur for HIV before the damn STATNOME test is done...nlol
W2play, I have read your posts for many years and have respected and appreciated them. I've seen you go round and round with the clown.
DNAG aside, (not to mention that DNAG came on board with Emory the moment the EPA for MK0518 became public, or the fact that in that 24 week period to date in Feb. "miraculous strides were made in the development of that compound) a cure for HIV has been found by Merck, at Emory:
In fact, most patients who had been treated on a variety of antiretroviral therapies who were given MK0518 - being developed by Merck - were able to suppress their bloodstream levels of virus to undetectable levels.
http://www.medpagetoday.com/InfectiousDisease/2006CROIMeeting/tb/2644
This is huge.
Can anybody on this board tell me if our technology participated in this? Can anybody tell me what other applications our technology at Emory could have been applied to?
Does anybody realize Wall Street has heard about this and is just waiting for validation to invest heavily in personalized medicine?
http://www.thestreet.com/markets/corrections/10337044.html
For the record, I own 1,377,222 shares of DNAG. Should I sell them and buy MRK?
Froogle, it's like that Barry White tune: Deeper..and Deeeperr...
This isn't too far off:
Isaacs said that further testing is underway and if those advanced studies go well, Merck will seek Food and Drug Administration approval for MK0518 in 2007. "We are very excited about these results," he told UPI.
WAS IT BUMPED UP FROM 72% TO 95% IN THE 24 WEEKS SINCE WE WE'RE INVOLVED?
MAKE OF IT WHAT YOU WILL...
That article doesn't state it but that compound eliminates 95% of HIV-3. The most virulent strain. That's almost done. So are you...
IS MERCK GOING TO CURE HIV AND CANCER IN FUTURE?
IS DNAG INVOLVED?
MAKE WHAT YOU WILL OF IT.
DENVER, Feb. 8 (UPI) -- Doctors said Wednesday that they are impressed by a new class of drug that destroys the virus that causes AIDS by attacking one of its key functions.
In early trials, two of these experimental "integrase inhibitors" were able to kill off more than 95 percent of the virus[/B] in just a few days of treatments - even in patients who were harboring virus resistant to other classes of drugs.
"This is some of the best data we have seen in salvage therapy in a long time," said Robin Isaacs, executive director for infectious diseases-clinical research at Merck, based in West Point, Penn.
"Today we have seen the fruition of more than 10 years of development," said John Mellors, professor of medicine at the University of Pittsburgh. "These are very impressive results."
In a presentation at the 13th Conference on Retroviruses and Opportunistic Infections in Denver, Isaacs told United Press International that work on the integrase inhibitor has been going on for more than a decade.
A previous Merck compound that had been through preliminary testing in people was discarded when toxicities appeared in animal models. The new compound, MK0518, appears to have few adverse side effects, despite a potent antiviral impact on human immunodeficiency virus (HIV), the pathogen that causes AIDS.
In a clinical trial, 80 patients were given MK0518 on top of their regular antiretroviral therapy - a therapy that wasn't holding the virus in check.
Depending on the experimental dosage of MK0518, 57 percent to 72 percent of the patients were able to reduce virus in their blood to levels that could not be detected by sensitive assays.
In contrast, only 5 of 27 patients - 19 percent - who were given a placebo pill in addition to the best available treatment could reduce their bloodstream levels of virus to undetectable levels.
"Integrase is absolutely essential for the virus to replicate," said Isaacs. The integrase enzyme is required to allow the virus to splice its RNA into the DNA of the host cell, turning the host cell into a factory to produce more viruses.
Integrase is one of the three main enzymes in the make-up of HIV. Scientists have already produced numerous drugs that interfere with the reverse transcriptase and protease enzymes. The integrase inhibitors have been eagerly awaited as another weapon to control HIV infection.
Isaacs said that further testing is underway and if those advanced studies go well, Merck will seek Food and Drug Administration approval for MK0518 in 2007. "We are very excited about these results," he told UPI.
Another study of a second integrase inhibitor also shows promise, according to Andrew Cheng, vice president for clinical research for Gilead Sciences, Forster City, Calif.
Cheng said his company's candidate, GS9137, appeared to reduce circulating HIV in every dosage used in a 10-day monotherapy trial.
He said that in his company's early studies, GS9137 was able to reduce bloodstream virus by as much as 99 percent in the 10 days of study. Further studies are also underway with this compound.
"The fact that Gilead's integrase inhibitor also worked well shows that this strategy is not a fluke," Mellors said in offering perspective. "This is a real target. This is validated. These results are as impressive as I've ever seen in the treatment of experienced patients."
http://www.hivdent.org/drugs1/drugDHKP0206.htm
Some more GREEN EGGS, FROGGY:
EMEND? (aprepitant) Helps Prevent Nausea/Vomiting for Breast Cancer Patients
the regimen including EMEND (day 1: EMEND 125 mg one hour before chemotherapy, ondansetron 8 mg 30-60 minutes before chemotherapy
EMEND? is a registered trademark of Merck & Co
http://www.medicalnewstoday.com/medicalnews.php?newsid=23074
Ondansetron
Through collaboration with the Moffitt Cancer Research Center in Tampa, FL, we are investigating the genetic basis of Ondansetron response. Ondansetron is an anti-emetic for the alleviation of post-operative nausea and vomiting (PONV), but normal doses of the drug do not elicit the desired effect in some patients. A genetic test for predicting Ondansetron response could help reduce extreme discomfort many patients feel after surgery.
March 29, 2004 DNAPrint™ genomics, Inc. Forms Joint Research Program with the H. Lee Moffitt Cancer Center and Research Institute
M2gen hiring just about everybody:
http://tbe.taleo.net/NA4/ats/careers/searchResults.jsp?org=MOFFITT&cws=1
Very possible DNAG has a hand in the cure for AIDS JMHO
Posted by Admin on 2006/10/10 21:36:00 (83 reads)
Basel, October 5, 2006 -- Exciting new clinical data demonstrate that 90 to 95 percent of treatment-experienced HIV patients who initiate therapy with FUZEON® (enfuvirtide) and the investigational integrase inhibitor MK-0518 can achieve undetectable levels of HIV (less than 400 copies per mL of blood)1. Such response rates have never been achieved in clinical trials of HIV patients living with drug-resistant virus. This significant antiviral effect achieved by adding FUZEON to other new drugs, known as the "FUZEON effect", has been consistently demonstrated across a number of studies.2 These data were presented at the 46th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
http://www.wadn.org/wadn/modules/news/article.php?storyid=674
Facts:
DNAPrint Genomics And Emory University Center For Medical Genomics Enter Agreement
8/17/2006
http://www.bioresearchonline.com/content/news/article.asp?docid=50ce4d82-1a41-4ff7-8216-dd3dc28a14be
09 January 2007
The Hope Clinic of the Emory Vaccine Center today announced that the Step Study, a multicenter international study of an HIV vaccine developed by Merck and Co., Inc., has successfully enrolled more than 2,800 people and expects to finalize enrollment within the next few months.
http://209.85.165.104/search?q=cache:haycA8RL8CMJ:whsc.emory.edu/press_releases2.cfm%3Fannouncement_....
Largest ever African HIV vaccine trial opens in South Africa
http://www.aidsmap.com/en/news/A5617C77-178E-457A-AD3C-0BA8AB9E3E0C.asp
Chris, my only agenda is I am a long time shareholder in DNAP/DNAG. I never posted much, but did keep up. I do believe we are on the threshold of what Frudakis outlined many years ago. Whether or not the common shareholders participate remains to be seen.
Advice:
Be very wary of the preferred shares being authorized
Anyway,
Do you recall years ago over on RB, that dnaprint.co/za site being posted and everybody wondering what it was. I just don't remember for certain.
Yes, it's all speculation, but...this isn't: We do have an agreement with Emory. Merck is using Emory. We do know that the vaccine was a joint collaboration b/w Pfizer and Merck. Pfizer has gone to Phase III trials while Merck has gone to Phase IIb to further develop safety and efficacy.
We have the High throughput capabilities b/w Dnaprint and Ellipsis. The question is: Are they going to be incorporating Ancestry to determine populations for testing this vaccine. We don't know. What work has been done on MK-0518 (see below)that could assist in the development of MRKAd5 HIV-1 ?
Why do I think they are going to use us? because they say this in the release: "and whether it would be effective in populations with pre-existing immunity to the viral vector used in the vaccine,
What does that mean?
This article is old and the approach is different but the problem stll exists. It's the same problem with every drug. It needs to be personalized.
Antiretroviral drug combination has been effective in dramatically reducing HIV-related mortality and morbidity. However, nearly half of HIV-infected patients still fail the treatment. Although genetic analyses of viral genomes from these patients show multiple-drug resistance mutations in the pol gene, the molecular mechanisms for the emergence of drug-resistance are not yet known. Therefore, it is important to delineate the mechanisms for multiple-drug resistance in order to more efficiently control HIV infection.
http://www.cbimms.duke.edu/gao.htm
I believe we are to be used, to some extent, as a control mechanism in this study. I also believe we need to advance our technology.
"This technology will be very useful for population stratification, and will serve as an extremely important quality control, particularly for large scale case control genetic association studies. Additionally, it will provide benefits in other areas, including pharmacogenetics," said Dr. MarkBouzyk, Director of Emory's Center for Medical Genomics.
http://www.bioportfolio.com/august_06/18_08_2006/DNAPrint_Genomics_and_Emory.html
I know our technology is being utilized at Emory since August 17, 2006 and I believe Merck is going to afford us the opportunity to advance that technology.
Notice dates. I DON’T believe in coincidence!! JMHO
SARASOTA, FL, August 17 / MARKET WIRE/ --
DNAPrint Genomics, Inc. (OTCBB: DNAG) todayannounced that it has entered into an agreement that will enable the Center for Medical Genomics, Emory University Department of Human Genetics to utilize the Company's Ancestry Informative Marker
August 17, 2006
Expanded Access Program for MK-0518, an Investigational HIV Integrase Inhibitor, Established for Patients With Limited Available Treatment Options
Worldwide Access Program Will Be Conducted Along With Phase III Studies
http://www.thebody.com/press/mk0518_access.html
MK-0518
MK-0518 is the first inhibitor of integrase-the step in HIV’s lifecycle where the HIV genome is inserted into the host’s DNA—to reach phase II/III efficacy trials. Two integrase inhibitors are now in the clinic,
and several preclinical integrase programs are underway in drug discovery programs around the world(see TAG’s preclinical ARV pipeline chart at
www.aidsinfonyc.org/tag/tx/pipeline2006a.html).
http://aidsinfonyc.org/tag/tagline/pipeline2006.pdf
I believe we’re going to be hearing a lot more about the drugs in the above link. We came on board with MK-0518 (which is a more potent drug than MRKAd5 HIV-1) and is now in Phase II/III after showing it was well tolerated with few side effects. . Do we have the technology?
http://www.bioportfolio.com/november_06/03_11_2006/Roche_presents_positive_new.html
2007 FEB 5 - (NewsRx.com) -- An update on recent developments released by Merck.
Levels of total cholesterol and triglycerides were not increased in HIV-infected patients taking MK-0518, an investigational integrase inhibitor being developed by Merck & Co., Inc., with tenofovir (Viread) and lamivudine (Epivir).
In contrast, increased levels of both lipid parameters were observed in patients taking efavirenz (Sustiva) combined with the same drugs.
The interim 24-week results are from an ongoing 48-week study in 198 treatment-naive HIV-infected patients,
MK-0518 belongs to a new class of investigational antiretroviral therapy agents called integrase inhibitors that inhibit the insertion of the HIV viral DNA into human DNA. Inhibiting integrase from performing this essential function blocks the ability of the virus to replicate and infect new cells. There are drugs in use that inhibit the other two enzymes involved in viral replication - protease and reverse transcriptase - but there are no approved drugs that inhibit integrase.
Important data, eh? I’ve read about this new class of drugs being used to stop the spread of cancer. Notice dates…study started when we came in and EAP was made public.
http://209.85.165.104/search?q=cache:0jZijX6DfvQJ:calibre.mworld.com/m/m.w%3Flp%3DGetStory%26id%3D24...
The further we spread the more validity that gets attached to our utility.
One thing. Either way, it sound like we’re in Mercks’ pocket. That means making us solvent. JMHO
Oh Yeah, there’s also M2gen , oh my…
We'll know soon.
For those who believe connecting the dots is futile: Just remember...people are convicted and sent to the gas chamber on circumstantial evidence.
Make of it what you will...GOOD LUCK!!
Actually, there was four days left on the original agreement. In all other filings during the agreement they outlined the agreement. Why would they leave that one line in saying they "instituted" a clinical development program. Maybe because they have?
Make of it what you will...